Global Human Recombinant Insulin Market Size By Product (Regular (short-acting) insulin, NPH (intermediate-acting) insulin, Premixed human insulins insulin), By Distribution Channel (Hospitals, Retail pharmacies, Online pharmacies), By Geographic Scope And Forecast

Human Recombinant Insulin Market Size And Forecast

Human Recombinant Insulin Market size was valued at USD 41.35 Billion in 2023 and is projected to reach USD 64.79 Billion by 2030, growing at a CAGR of 8.25% from 2024 to 2030.

The rise in the number of diabetic patients and the growing medical reimbursement setup across different regions are the key factors driving the growth of the global Human Recombinant Insulin Market. Further, the advancement in activities of research and development by various government and private organizations is expected to propel the growth of the market. The increase in investments in diabetes research activities has resulted in influencing the demand for the market. Moreover, the recombinant insulin market is following a small-scale process for development by offering analog products coupled with custom media formulations owing to promote market growth. The Global Human Recombinant Insulin Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Human Recombinant Insulin Market Definition

Recombinant insulin is one of the first products of biotechnology. Recombinant insulin is synthetic insulin obtained by utilizing recombinant DNA technology. They replace the animal insulins and semisynthetic insulin resulting from the modification of animal insulins. These are created to supply the need for a consistent and sufficient worldwide demand. Insulin replacement therapy is the standard of care for patients with type 1 and type 2 diabetes mellitus.

With the advancement in recombinant DNA technology, recombinant human insulin became available in huge amounts. This is provided by biosynthesis in microorganisms. Offering a reliable supply of hormones across different regions at a reasonable cost. These have a superior level of purity and consistent quality as compare with synthetic insulin. Patients with diabetes can be safely and effectively transferred from animal and semisynthetic human insulin to recombinant human insulin with no change expected in insulin dose.

Global Human Recombinant Insulin Market Overview

The Human Recombinant Insulin Market is expected to grow owing to the increase in the number of diabetic patients. The favorable medical reimbursement in emerging nations helping to reduce the risk factors leading to diabetes is another key factor responsible for market growth. This has intensified the market availability of generic human insulin products and the arrangement for human insulin analogs has projected the demand for the market across the globe. The growing geriatric population expected patent expiry of mainly human analog drugs is expected to promote the growth of the market.

Further, the growing scope of R&D for drug discovery and up-gradation of technological advancement in human insulin delivery devices has facilitated the demand for the market across regions. Moreover, the increasing government schemes to support the expansion and commercialization of efficient biosimilar are further expanding the market. Many governments and private research organizations have started involving in different R&D activities.

These have evolved innovative treatments in diabetes care to grow the efficacy of human insulin, reduce the harm of diabetes and other related disorders and decrease its affliction. This has promoted the demand for the Human Recombinant Insulin Market in different regions across the globe. However, the unaffordability of the population owing to the high cost of insulin can restrain the growth of the global Human Recombinant Insulin Market.

Global Human Recombinant Insulin MarketSegmentation Analysis

The Global Human Recombinant Insulin Market is segmented based on Product, Distribution Channel, And Geography.

Human Recombinant Insulin Market, By Product

• Regular (short-acting) insulin
• NPH (intermediate-acting) insulin
• Premixed human insulins insulin

Based on Product, the market is bifurcated into Regular (short-acting) insulin, NPH (intermediate-acting) insulin, and Premixed human insulins insulin. The regular (short-acting) insulin is anticipated to witness the highest growth of the market. These insulins are mainly consumed before meals and acre gaining popularity around the globe.

Human Recombinant Insulin Market, By Distribution Channel

• Hospitals
• Retail pharmacies
• Online pharmacies
• Others

Based on Distribution Channel, the market is segmented into Hospitals, Retail pharmacies, Online pharmacies, and Others. Retail pharmacies are expected to hold the highest share of the market owing to their growing adoption rate of human insulin delivery systems. Further, the growing technology advancement of insulin injectables has resulted in augmenting the growth of the retail pharmacies segment. Moreover, the growing number of retail pharmacies across developing and developed countries have anticipated the growth of the market.

Human Recombinant Insulin Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Geography, the Global Human Recombinant Insulin Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is one of the largest growing regions owing to the increasing technological developments in insulin delivery products.

Key Players

The “Global Human Recombinant Insulin Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Biocon, Eli Lilly and Company, Zhuhai United Laboratories Co Ltd., Dongbao Enterprise Group Co Ltd., Sanofi S.A., Novo Nordisk A/S, Gan & Lee Pharmaceuticals, Ltd., Bioton S.A., Julphar Gulf Pharmaceutical Industries, and Wanbang Biopharmaceuticals Co Ltd. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally

Key Developments

Partnerships, Collaborations, and Agreements

• In March 2021, Biocon Ltd, a global biopharmaceutical company focused on innovation, today announced a collaboration between Biocon Pharma Limited, a wholly-owned subsidiary of Biocon Limited, and Libbs Farmaceutica, a leading pharmaceuticals company in Brazil, to launch generic drugs in the world’s sixth most populous country. This collaboration, which marks the introduction of Biocon’s generic formulations into Latin America, builds on the company’s previous collaboration with Libbs, which began in 2017 with the launch of the biosimilar Trastuzumab in Brazil. It demonstrates Biocon’s dedication to making affordable healthcare available to people all around the world by building a strong worldwide presence for its formulations portfolio, either directly or through strategic partnerships.

Mergers and Acquisitions

• In November 2020, Biotechnology behemoth Biocon announced that it has decided to acquire a 26% share in Hinduja Renewables Two Pvt Ltd on a fully diluted basis for Rs 5.91 crore. The goal of the stake purchase is to increase the use of renewable energy.
• In September 2019, Biocon Ltd, Asia’s leading biopharmaceutical business, announced that its subsidiary, Biocon Biologics, has purchased R&D capital assets for a 60,000 square foot state-of-the-art ‘bench to pilot scale’ Biologics research facility at TICEL Bio Park in Chennai, India. Pfizer Healthcare India Ltd has sold these assets to Biocon Biologics.

Product Launches and Product Expansions

• In August 2020, the Bengaluru-based firm, Biocon’s subsidiary Biocon Biologics and partner Mylan have released insulin glargine injectable under the brand name Semglee in the US market. Biocon Biologics India and Mylan have released the medication in the United States in the vial and pre-filled pen formats, according to Biocon. It is approved to help regulate high blood sugar levels in adults and children with type 1 diabetes, as well as individuals with type 2 diabetes. Mylan, which is in charge of commercialization in the United States, would sell Semglee for $147.98 for every package of five 3ml pens and $98.65 per 10ml vial, making it the cheapest brand of insulin glargine available in the country.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any